Adherence as a Value Lever

Almost everything in this curriculum concerns reducing utilization of something. Medication adherence runs the other way, and getting that direction right is the highest-value pharmacy insight available to a risk-bearing organization.

The logic

A patient with heart failure who takes their medication has fewer decompensations and fewer admissions. A patient with diabetes who takes theirs has fewer complications. A patient who stops taking either, whether from cost, side effects, complexity, or simply losing track, generates expensive events that the medication was preventing.

For an organization accountable for total cost of care, the arithmetic usually favors more medication rather than less for these conditions. The Medicare Advantage course noted that Star Ratings include medication adherence measures for exactly this reason: the plans bearing full risk concluded that adherence was worth measuring and rewarding.

Where adherence breaks

The failure points are mundane and each has a corresponding intervention:

Why patients stop	What addresses it
Cost at the pharmacy counter	Formulary tier placement, copay assistance, low-cost generic alternatives
Complexity and pill burden	Regimen simplification, synchronization, combination products
Side effects	Proactive follow-up after initiation, which is when most discontinuation occurs
Never picked it up in the first place	Primary nonadherence reporting, which requires pharmacy claims data
Ran out and did not refill	Refill reminders, 90-day fills, automatic refill programs

The fourth row is worth dwelling on. Primary nonadherence, where a prescription is written and never filled, is invisible to a prescriber who sees only their own order. It is visible in pharmacy claims. This is a direct instance of the data course’s point that the organization can only manage what it can see, and it is one reason Module 2’s benchmark question matters: an organization without pharmacy data cannot detect the patients who never started.

The design implication

If adherence is worth increasing, then plan design and management should reflect that:

• Value-based insurance design lowers or eliminates cost sharing for high-value medications rather than applying uniform tiers, on the reasoning that a copay is a barrier the patient’s clinical need does not care about.
• Utilization management should be targeted at therapeutic duplication, inappropriate prescribing, and expensive alternatives to equivalent drugs, rather than applied broadly across chronic maintenance therapy.
• Adherence should be a measured outcome in any arrangement that includes pharmacy spend, or the incentive will run the wrong way by default.

Worth remembering: this is the strongest available argument for carving pharmacy into total cost of care rather than managing it separately. A pharmacy budget managed on its own will treat every prescription as a cost, and the person managing it will be evaluated on reducing that line. The same organization measured on total cost has a reason to pay for the statin, call the patient who did not refill it, and count that as a win. The boundary determines the behavior, which is the recurring lesson of this curriculum applied to the fastest-growing line in health care.

Key takeaways

• For chronic disease medications, an organization at risk for total cost generally benefits from higher adherence.
• Adherence fails through cost, complexity, side effects, primary nonadherence, and refill gaps, each with a distinct intervention.
• Prescriptions never filled are invisible without pharmacy claims data.
• Carving pharmacy into total cost of care aligns the incentive; managing it as a separate budget inverts it.

Sources

• KFF, A Current Snapshot of the Medicare Part D Prescription Drug Benefit (opens in a new tab)
• 42 CFR 425.20, Medicare Shared Savings Program definitions (opens in a new tab)